Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2 ...
The global trial was designed to evaluate Abecma, a CAR-T cell therapy, with lenalidomide, a multiple myeloma therapy marketed by Bristol Myers (BMY) as Revlimid, versus lenalidomide monotherapy.
2seventy bio and Bristol Myers Squibb are pulling the plug on a late-stage study of their Abecma gene therapy in certain people newly diagnosed with the blood cancer multiple myeloma.